Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
GYRE THERAPEUTICS, INC.
Bear Case (25th pct.)
-88.3% vs price
Base Case (Median)
-87.5% vs price
Bull Case (75th pct.)
-77.1% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $0.80 | -87.5% | High (40%) |
| EV/EBITDA | $2.14 | -66.7% | Medium (20%) |
| Earnings Power Value | $0.70 | -89.1% | Medium (50%) |
Based on 3 out of 7 methods, GYRE appears overvalued at the current price of $6.41. The base case fair value of $0.80 implies 87.5% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.